Engineered proteins to restore and enhance neurotransmitter release
Related Experiment Video
Updated: Nov 9, 2026

Chemogenetic Regulation in Reprogrammed Stem Cell-derived Precursor Cells in Treating Neurodegenerative Diseases
Published on: May 2, 2025
Abstract:
Synapse dysfunction is a hallmark feature of many neurological diseases. Synaptic transmission is initiated in nerve terminals, where active zone protein complexes control vesicle fusion for neurotransmitter release. Here, we engineer proteins that mediate active zone functions and demonstrate their use for reconstituting and strengthening neurotransmission. A protein composed of Ca V β4 and the RIM1 zinc finger, β4-Zn, restored neurotransmitter release after active zone disruption through recruitment of Munc13. We develop β4-MC, derived from the Munc13-1 MUN and C2C domains, which bypasses Munc13 recruitment and directly mediates vesicle docking, priming and fusion after active zone disruption. In β4-MC, MUN domain functions are dispensable for docking, but active MUN and C2C domains are both necessary for neurotransmitter release. In wild-type mouse and human neurons, β4-MC but not β4-Zn strengthens neurotransmitter release. Furthermore, β4-Zn and β4-MC restore and enhance dopamine release in the mouse striatum, respectively. Hence, β4 proteins are engineered secretory proteins with therapeutic potential as enhancers of synaptic function.
More Related Videos
Related Concept Videos
Drugs Affecting Neurotransmitter Synthesis
Neurochemical Transmission: Sites of Drug Action
Drugs Affecting Neurotransmitter Release or Uptake
Role of Neurotransmitters in Memory
Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is critical for...
Neurotransmitters
Neurotransmitters

